# RenovoRx Reports Record First Quarter 2026: Increasing Revenue by 136% Quarter-over-Quarter
Canonical URL: https://biopharmsignal.com/news/RNXT/renovorx-reports-record-first-quarter-2026-increasing-revenue-by-136-quarter-over-quarter
Ticker: RNXT
Company: RenovoRx
Source: RenovoRx
Published: 2026-05-14 20:05 EST
Original Source URL: https://ir.renovorx.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-06-11 12:30 EST — [RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer](https://biopharmsignal.com/news/RNXT/renovorx-highlights-peer-reviewed-publication-supporting-intra-arterial-gemcitab-165aa510) — Source: RenovoRx
- 2026-06-04 12:30 EST — [RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd](https://biopharmsignal.com/news/RNXT/renovorx-ceo-shaun-bagai-to-present-at-the-iaccess-alpha-virtual-best-ideas-summer-investment-conference-2026-on-june-23rd) — Source: RenovoRx
- 2026-05-28 12:30 EST — [RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer](https://biopharmsignal.com/news/RNXT/renovorx-announces-fda-orphan-drug-designation-granted-oxaliplatin-for-the-treatment-of-pancreatic-cancer) — Source: RenovoRx
- 2026-05-26 12:30 EST — [RenovoRx Announces Promising Pharmacokinetic Data Using the TAMP™ Platform Presented at the 2026 ASCO Annual Meeting](https://biopharmsignal.com/news/RNXT/renovorx-announces-promising-pharmacokinetic-data-using-the-tamptm-platform-presented-at-the-2026-asco-annual-meeting) — Source: RenovoRx
- 2026-05-19 12:30 EST — [RenovoRx to Present at the Alliance Global Partners Virtual Annual Healthcare Company Showcase on May 20th](https://biopharmsignal.com/news/RNXT/renovorx-to-present-at-the-alliance-global-partners-virtual-annual-healthcare-company-showcase-on-may-20th) — Source: RenovoRx
## Related News
- 2026-07-22 20:05 EST — AZTA — [Azenta Announces Fiscal 2026 Third Quarter Conference Call and Webcast](https://biopharmsignal.com/news/AZTA/azenta-announces-fiscal-2026-third-quarter-conference-call-and-webcast-48419fff)
- 2026-07-22 20:05 EST — VKTX — [Viking Therapeutics to Report Financial Results for Second Quarter 2026 on July 29, 2026](https://biopharmsignal.com/news/VKTX/viking-therapeutics-to-report-financial-results-for-second-quarter-2026-on-july--bbf2553f)
- 2026-07-22 20:01 EST — AXON — [Axon to Release Second Quarter 2026 Earnings on August 5, 2026](https://biopharmsignal.com/news/AXON/axon-to-release-second-quarter-2026-earnings-on-august-5-2026-66120902)
- 2026-07-22 12:39 EST — ARTL — [New Analysis of Over 50 Studies Showed that All the Non-Prescription CBD Products Researched Fell Short of Therapeutic Efficacy — Reinforcing the Case for Artelo's Optimized ART12.11 CBD Composition](https://biopharmsignal.com/news/ARTL/new-analysis-of-over-50-studies-showed-that-all-the-non-prescription-cbd-product-a3445432)
- 2026-07-22 12:30 EST — NRSN — [NeuroSense Advances PrimeC Toward New Drug Submission to Health Canada for ALS](https://biopharmsignal.com/news/NRSN/neurosense-advances-primec-toward-new-drug-submission-to-health-canada-for-als-721c198c)